 |
  |
26.07.2010 AbD Serotec Secures Exclusive
Worldwide License to Key Diagnostic Antibody
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that its research and diagnostic antibodies unit AbD
Serotec has signed an exclusive license agreement with UCL Business
PLC (UCLB), the technology development company of University College
London (UCL). The agreement provides AbD Serotec with worldwide
exclusive access to a potent anti-PTH antibody for commercial use in
research and diagnostic applications. The anti-PTH antibody forms
the basis of an existing relationship between AbD Serotec and a
leading diagnostic company which markets clinical parathyroid
hormone assays.
 |
|
|
 |
|
26.07.2010 Oxford BioMedica Announces FDA Approval for
TroVax® Phase II Study in Prostate Cancer
|
Oxford
Biomedica
(“Oxford BioMedica” or “the Company”) (LSE: OXB),
a leading gene therapy company, announces that it has
received approval from the US Food and Drug
Administration (FDA) and Recombinant DNA Advisory
Committee (RAC) to initiate a clinical Phase II study in
the United States to assess the activity of TroVax®
(MVA-5T4) in patients with progressive hormone
refractory prostate cancer (HRPC).
|
|
|
 |
|
26.07.2010 Clontech Laboratories, Inc. & TET
Systems Announce the Broadening of Their License Agreement And the
Upcoming Launch of The New Tet-On® 3G™ Inducible Expression System |
Clontech
Laboratories, Inc., a wholly-owned subsidiary of
Takara Bio Inc., and TET Systems
(TET), a privately-held German biotech company based in Heidelberg,
today announced that they have signed an amendment to their existing
license agreement. Under the expanded license agreement, Clontech
obtains rights to develop, manufacture and commercialize novel Tet
Systems products as the Tet-On® 3G™ Inducible Expression System (www.clontech.com/teton3g
).
|
|
|
|
|
|
21.07.2010 CCS
Cell Culture Service celebrates its 10th
anniversary |
CCS
Cell Culture Service GmbH,
which was founded in early 2000 by the Hamburg scientist Dr.
Oliver Klotzsche and his three partners, was originally dedicated to
provide all kinds of cell culture related services. Within the last
decade the company has advanced to one of the leading suppliers of
cells and cell based reagents for pharmaceutical industries.
Meanwhile CCS has 20 employees. Last year CCS launched its subsidiary at the east coast of the
USA
and has thereby opened a new chapter in the book of its success.
|
|
|
 |
|
21.07.2010 Phillips and Dako join
forces in Digital Pathology |
Royal Philips Electronics (NYSE:
PHG, AEX: PHI) and
Dako,
a Danish company specializing in tissue-based cancer
diagnostics, today announced that they have signed an
agreement to integrate a selection of Dako’s image
analysis applications into Philips’ future digital
pathology solutions.
|
|
|
|
|
|
21.07.2010 AiCuris Presents Mechanism of Action Investigations of
Its Novel Anti-HCMV Drug AIC246 at The International Herpesvirus
Workshop |
AiCuris announced today publication of
preclinical data on AIC246, at the International Herpesvirus
Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246
is a novel anti-HCMV drug currently in clinical phase 2 testing.
|
|
|
 |
|
20.07.2010 Genentech Provides Update From Avastin FDA Advisory
Committee Meeting |
Genentech, Inc.,
a member of the
Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced
today that the U.S. Food and Drug Administration (FDA)
Oncologic Drugs Advisory Committee (ODAC) voted 12 to
one that use of Avastin® (bevacizumab) in
combination with paclitaxel for previously untreated
(first-line) advanced HER2-negative breast cancer be
removed from Avastin’s U.S. label. The committee’s
vote does not affect the current availability of Avastin
for people with advanced HER2-negative breast cancer in
the United States. The FDA is expected to make a
decision on the first-line use of Avastin in combination
with certain types of chemotherapy in the United States
for advanced breast cancer by September 17, 2010.
|
| |
 |
|
|
|
RNA offers a safer way to
reprogram cells |
 |
In recent years, scientists have
shown that they can reprogram human skin cells to an immature
state that allows the cells to become any type of cell. This
ability, known as pluripotency, holds the promise of treating
diseases such as diabetes and Parkinson's disease by
transforming the patients' own cells into replacements for the
nonfunctioning tissue.
|
|
|
|
|
|
|
Antibody may help treat and prevent
influenza outbreaks |
 |
Researchers have discovered a
monoclonal antibody that is effective against
"Avian" H5N1, seasonal H1N1 and the 2009 "Swine"
H1N1 influenza. Scientists at Sea Lane
Biotechnologies, LLC, in collaboration with Mt.
Sinai School of Medicine, St. Jude Research
Hospital and the Scripps Research Institute,
have shown that this antibody potently prevents
and treats the Swine H1N1 influenza in mouse
models of the disease.
|
|
|
|
  |
|
Dark chocolate lowers blood
pressure |
 |
For people with hypertension,
eating dark chocolate can significantly reduce blood
pressure. Researchers writing in the open access
journal BMC Medicine combined the results of 15 studies
into the effects of flavanols, the compounds in
chocolate which cause dilation of blood vessels, on
blood pressure.
|
|
|
|
 |
|
New measurement of DNA could help identify
most viable embryos for IVF |
 |
Scientists from the University of Warwick and University
Hospitals Coventry and Warwickshire NHS Trust, are the
first to directly measure a specific region of DNA in
human embryos. The length of this region could be a
quality marker for embryonic development.
|
|
|
|
|
|
|
Saint Louis University
investigators perfect new version of blood-regulator thrombin |
 |
In research led by a
Saint Louis University investigator, molecular
biologists have discovered a way to harness the enzyme
thrombin's anti-blood clotting properties. The finding
opens the door to new medications that will treat
diseases related to thrombosis, the presence of blood
clots in blood vessels, which is responsible for nearly
a third of all deaths in the U.S.
|
|
|
|
|
|
|
Sex lives of patients are negatively
affected by rheumatoid arthritis and SLE |
 |
Systemic Lupus Erythematosus (SLE) patients from Brazil
and Rheumatoid Arthritis (RA) patients from France
report that their rheumatic conditions negatively affect
their emotional relationships and sex lives, according
to research presented today at EULAR 2010, the Annual
Congress of the European League Against Rheumatism in
Rome, Italy. Furthermore, findings of the French study
specifically revealed a strong correlation between RA
disease severity and impact on sex life.
|
|
All rights reserved